Literature DB >> 34530700

Prevalence and Population Attributable Risk for Early Chronic Obstructive Pulmonary Disease in U.S. Hispanic/Latino Individuals.

Fariha Khalid1, Wei Wang2,3, David Mannino4, Alejandro A Diaz5,3.   

Abstract

Rationale: In predominantly White populations, early chronic obstructive pulmonary disease (COPD) (i.e., COPD in people aged <50 yr) has been linked to higher hospitalization rates and mortality; however, the prevalence, risk factors, and population attributable risk (PAR) of early COPD remain to be determined in non-White populations.
Objectives: We aimed to examine the prevalence, risk factors, and PARs of early COPD among Hispanic/Latino individuals, the largest U.S. minority group.
Methods: We used baseline data from the Hispanic Community Health Study/Study of Latinos, a population-based probability sample of 16,415 Hispanic/Latino individuals aged 18-74 years. Participants aged <50 years were included (N = 7,323). Early COPD was defined as a forced expiratory volume in 1 second to forced vital capacity ratio less than the lower limit of normal. We used survey logistic regression analysis to identify risk factors and estimate the prevalence of early COPD. PARs of the risk factors identified were estimated.
Results: A total of 524 participants met the criteria for early COPD, yielding a sex- and age-adjusted prevalence of 7.6% (95% confidence interval [CI], 6.8-8.6). Asthma (odds ratio [OR], 3.37; 95% CI, 2.57-4.41), smoking status (ever vs. never; OR, 1.65; 95% CI, 1.24-2.20), and chronic sinusitis (OR, 1.71; 95% CI, 1.09-2.66) were associated with increased odds of early COPD. Immigrants versus U.S.-born individuals have lower odds of early COPD (age at immigration <15 yr and living in the United States <10 yr; OR, 0.94; 95% CI, 0.39-2.27; age at immigration <15 yr and living in the United States ⩾10 yr; OR, 0.55; 95% CI, 0.37-0.84; age at immigration ⩾15 yr and living in the United States <10 yr; OR, 0.86; 95% CI, 0.57-1.30; and age at immigration ⩾15 yr and living in the United States ⩾10 yr; OR, 0.63; 95% CI, 0.42-0.95). Among smokers, pack-years was not associated with early COPD (5-9.9 vs. <5 pack-years; OR, 1.04; 95% CI, 0.59-1.82; ⩾10 vs. <5 pack-years; OR, 1.20; 95% CI, 0.74-1.94). The mean PAR for asthma, smoking status, and chronic sinusitis was 26.3% (95% CI, 22.1-30.3), 22.4% (95% CI, 17.4-27.1), and 6.9% (95% CI, 4.3-9.4), respectively. Conclusions: Among U.S. Hispanic/Latino individuals, asthma is one of the most important risk factors for early COPD, followed by smoking and chronic sinusitis. Immigrants appear to have a lower risk of early COPD than U.S.-born Hispanic/Latino individuals.

Entities:  

Keywords:  COPD; Hispanic/Latino; asthma; chronic sinusitis; smoking

Mesh:

Year:  2022        PMID: 34530700      PMCID: PMC8937229          DOI: 10.1513/AnnalsATS.202103-253OC

Source DB:  PubMed          Journal:  Ann Am Thorac Soc        ISSN: 2325-6621


  33 in total

1.  Interpretative strategies for lung function tests.

Authors:  R Pellegrino; G Viegi; V Brusasco; R O Crapo; F Burgos; R Casaburi; A Coates; C P M van der Grinten; P Gustafsson; J Hankinson; R Jensen; D C Johnson; N MacIntyre; R McKay; M R Miller; D Navajas; O F Pedersen; J Wanger
Journal:  Eur Respir J       Date:  2005-11       Impact factor: 16.671

2.  Association of birthplace and occupational exposures with chronic bronchitis in US Hispanics/Latinos, 2008-2011.

Authors:  Victor Kim; Wei Wang; David Mannino; Alejandro Diaz
Journal:  Occup Environ Med       Date:  2020-03-12       Impact factor: 4.402

3.  Spirometric reference values from a sample of the general U.S. population.

Authors:  J L Hankinson; J R Odencrantz; K B Fedan
Journal:  Am J Respir Crit Care Med       Date:  1999-01       Impact factor: 21.405

4.  Prevalence, Characteristics, and Prognosis of Early Chronic Obstructive Pulmonary Disease. The Copenhagen General Population Study.

Authors:  Yunus Çolak; Shoaib Afzal; Børge G Nordestgaard; Jørgen Vestbo; Peter Lange
Journal:  Am J Respir Crit Care Med       Date:  2020-03-15       Impact factor: 21.405

Review 5.  An official American Thoracic Society public policy statement: Novel risk factors and the global burden of chronic obstructive pulmonary disease.

Authors:  Mark D Eisner; Nicholas Anthonisen; David Coultas; Nino Kuenzli; Rogelio Perez-Padilla; Dirkje Postma; Isabelle Romieu; Edwin K Silverman; John R Balmes
Journal:  Am J Respir Crit Care Med       Date:  2010-09-01       Impact factor: 21.405

6.  Trends in the prevalence of obstructive and restrictive lung function among adults in the United States: findings from the National Health and Nutrition Examination surveys from 1988-1994 to 2007-2010.

Authors:  Earl S Ford; David M Mannino; Anne G Wheaton; Wayne H Giles; Letitia Presley-Cantrell; Janet B Croft
Journal:  Chest       Date:  2013-05       Impact factor: 9.410

Review 7.  What is early COPD and why is it important?

Authors:  Joan B Soriano; Francesca Polverino; Borja G Cosio
Journal:  Eur Respir J       Date:  2018-12-06       Impact factor: 16.671

8.  The association between childhood asthma and adult chronic obstructive pulmonary disease.

Authors:  Andrew Tai; Haily Tran; Mary Roberts; Nadeene Clarke; John Wilson; Colin F Robertson
Journal:  Thorax       Date:  2014-03-19       Impact factor: 9.139

9.  Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report. GOLD Executive Summary.

Authors:  Claus F Vogelmeier; Gerard J Criner; Fernando J Martinez; Antonio Anzueto; Peter J Barnes; Jean Bourbeau; Bartolome R Celli; Rongchang Chen; Marc Decramer; Leonardo M Fabbri; Peter Frith; David M G Halpin; M Victorina López Varela; Masaharu Nishimura; Nicolas Roche; Roberto Rodriguez-Roisin; Don D Sin; Dave Singh; Robert Stockley; Jørgen Vestbo; Jadwiga A Wedzicha; Alvar Agustí
Journal:  Am J Respir Crit Care Med       Date:  2017-03-01       Impact factor: 21.405

10.  COPDGene® 2019: Redefining the Diagnosis of Chronic Obstructive Pulmonary Disease.

Authors:  Katherine E Lowe; Elizabeth A Regan; Antonio Anzueto; Erin Austin; John H M Austin; Terri H Beaty; Panayiotis V Benos; Christopher J Benway; Surya P Bhatt; Eugene R Bleecker; Sandeep Bodduluri; Jessica Bon; Aladin M Boriek; Adel Re Boueiz; Russell P Bowler; Matthew Budoff; Richard Casaburi; Peter J Castaldi; Jean-Paul Charbonnier; Michael H Cho; Alejandro Comellas; Douglas Conrad; Corinne Costa Davis; Gerard J Criner; Douglas Curran-Everett; Jeffrey L Curtis; Dawn L DeMeo; Alejandro A Diaz; Mark T Dransfield; Jennifer G Dy; Ashraf Fawzy; Margaret Fleming; Eric L Flenaugh; Marilyn G Foreman; Spyridon Fortis; Hirut Gebrekristos; Sarah Grant; Philippe A Grenier; Tian Gu; Abhya Gupta; MeiLan K Han; Nicola A Hanania; Nadia N Hansel; Lystra P Hayden; Craig P Hersh; Brian D Hobbs; Eric A Hoffman; James C Hogg; John E Hokanson; Karin F Hoth; Albert Hsiao; Stephen Humphries; Kathleen Jacobs; Francine L Jacobson; Ella A Kazerooni; Victor Kim; Woo Jin Kim; Gregory L Kinney; Harald Koegler; Sharon M Lutz; David A Lynch; Neil R MacIntye; Barry J Make; Nathaniel Marchetti; Fernando J Martinez; Diego J Maselli; Anne M Mathews; Meredith C McCormack; Merry-Lynn N McDonald; Charlene E McEvoy; Matthew Moll; Sarah S Molye; Susan Murray; Hrudaya Nath; John D Newell; Mariaelena Occhipinti; Matteo Paoletti; Trisha Parekh; Massimo Pistolesi; Katherine A Pratte; Nirupama Putcha; Margaret Ragland; Joseph M Reinhardt; Stephen I Rennard; Richard A Rosiello; James C Ross; Harry B Rossiter; Ingo Ruczinski; Raul San Jose Estepar; Frank C Sciurba; Jessica C Sieren; Harjinder Singh; Xavier Soler; Robert M Steiner; Matthew J Strand; William W Stringer; Ruth Tal-Singer; Byron Thomashow; Gonzalo Vegas Sánchez-Ferrero; John W Walsh; Emily S Wan; George R Washko; J Michael Wells; Chris H Wendt; Gloria Westney; Ava Wilson; Robert A Wise; Andrew Yen; Kendra Young; Jeong Yun; Edwin K Silverman; James D Crapo
Journal:  Chronic Obstr Pulm Dis       Date:  2019-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.